Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma

被引：42
|
作者：
Mehta, Anurag [1 ]
Gupta, Arjun [1 ]
Hannallah, Franck [1 ]
Koshy, Thomas [2 ]
Reimold, Sharon [2 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Cardiol, Dallas, TX 75390 USA
来源：
MELANOMA RESEARCH | 2016年 / 26卷 / 03期
关键词：
D O I：
10.1097/CMR.0000000000000251
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：319 / 320
页数：2
相关论文
共 50 条
  • [31] IMMUNE-RELATED MYOCARDITIS AND CONDUCTION ABNORMALITIES SECONDARY TO COMBINATION IMMUNOTHERAPY TREATMENT WITH IPILIMUMAB/NIVOLUMAB IN A PATIENT WITH MERKEL CELL CARCINOMA
    Velez, Miguel Gonzalez
    Suero-Abreu, Giselle
    Duma, Narjust
    Gutierrez, Martin
    Proverbs-Singh, Tracy
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 2617 - 2617
  • [32] Adverse events and estimated costs with the combination of ipilimumab and nivolumab in metastatic melanoma patients.
    Moura, Bianca Gautron
    Gerard, Camille Lea
    Testart, Nathalie
    Caikovsky, Marian
    Wicky, Alexandre M.
    Aedo-Lopez, Veronica
    Berthod, Gregoire
    Homicsko, Krisztian
    Prior, John
    Dromain, Clarisse
    Kandalaft, Lana E.
    Cuendet, Michel A.
    Michielin, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] MANAGEMENT OF TREATMENT-RELATED ADVERSE EVENTS ASSOCIATED WITH NIVOLUMAB AND IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH METASTATIC MELANOMA, NSCLC, OR RCC.
    Kannan, Rajni
    Mitchell, Teresa
    Sherry, Victoria
    Pons, Alice
    Kreamer, Kristen
    Shames, Yelena
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [34] Fulminant hepatitis as an immune-related adverse event after nivolumab treatment
    Inamori, Osamu
    Miyagawa-Hayashino, Aya
    Ueno, Akihisa
    Hongo, Fumiya
    Sonobe, Yuta
    Hojo, Tomohito
    Konishi, Eiichi
    PATHOLOGY INTERNATIONAL, 2019, 69 (07) : 434 - 436
  • [35] Experience of immune-related adverse events associated with ipilimumab and nivolumab in a single center.
    Rapoport, Bernardo Leon
    Smit, Teresa
    van Eeden, Ronwyn
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [36] Ipilimumab/nivolumab/pembrolizumabPancreatic atrophy and immune-related adverse events: 31 case reports
    Reactions Weekly, 2019, 1735 (1) : 162 - 162
  • [37] Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Hayase, T.
    Washino, S.
    Shirotake, S.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Miura, Y.
    Hyodo, Y.
    Izumi, K.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1489
  • [38] Sacroiliitis as an immune-related adverse event of pembrolizumb treatment for melanoma
    Araujo, F. C.
    Afonso, P. D.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2022, 51 (04) : 342 - 343
  • [39] Ipilimumab/nivolumab/relatlimabHyperprogression of metastatic vaginal melanoma and myocarditis: case report
    Reactions Weekly, 2021, 1852 (1) : 248 - 248
  • [40] Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab
    Maloney, Anna K.
    Giobbie-Hurder, Anita
    Katukota, Nikita
    Fogarasi, Miklos C.
    Ott, Patrick A.
    Hodi, F. Stephen
    Sussman, Tamara A.
    Silk, Ann W.
    Haq, Rizwan
    Liu, David
    Insco, Megan
    Buchbinder, Elizabeth, I
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08)
12345